A bacterial injection system controlled by light

Molecular principle of the LITESEC system. In the dark (left), a T3SS component, which is necessary for the injection (red), is anchored to the bacterial membrane.

Credit: Max Planck Institute for terrestrial Microbiology/Diepold

By coupling a bacterial injection system with a light-controlled molecular switch, scientists are able to inject proteins into eukaryontic cells

When bacteria such as Salmonella or Yersinia cause fever, diarrhoea or abdominal pain, tiny “injection needles” are at work: their type 3 secretion system, or T3SS for short, shoots bacterial virulence proteins directly into the eukaryotic host cells. Researchers have thought of using bacterial injection devices to introduce proteins into eukaryotic cells. A Max Planck research team has now succeeded in controlling the injection system optogenetically, i.e. with light. In the future this will enable to use the system in biotechnological or medical applications.

The T3SS is essential for virulence in many important human pathogens, including Salmonella, Shigella, and pathogenic Escherichia coli, that cause several millions of deaths per year. It is also important in hospital infections, for example by Pseudomonas aeruginosa, where presence of a functional T3SS is associated with higher mortality in animal models and increased antibiotic resistance, severe disease, and a bad prognosis in infected humans.

Consequently, the T3SS is considered a central target for potential therapeutics that could impair its function and prevent infections. On the other hand, hijacking this bacterial system would offer the chance for controlled protein delivery to host cells through the T3SS, like in a trojanic horse. Protein injection through T3SS is fast and efficient: a single injectisome can transfer several thousand effector proteins in few seconds.

However, as powerful as the T3SS injection system is, it is far from accurate – much to the disappointment of the researchers. „As soon as a T3SS contacts any host cell, it fires its load immediately. This is unfavourable for applications in biotechnology or medicine, where we want to target specific cell types, for example in tumour therapy“, says Andreas Diepold, Research group leader at the Max-Planck-Institute for Terrestrial Microbiology in Marburg.

Protein injection via on/off switch

But now Andreas Diepold and his team have come a big step closer to this goal: they succeeded in controlling the T3SS injectisome using a molecular light switch. This will enable scientists to inject proteins into eukaryotic cells at a precise time and place. During my postdoctoral fellowship in Oxford, I discovered that some parts of the T3SS are dynamic“, Andreas Diepold recalls. „They are constantly exchanged between this apparatus and the interior of the cell.“ The scientist applied his findings to the young research field of optogenetics. The principle of this technique is that protein interactions can be controlled with millisecond speed by changing their conformation when stimulated with light of specific wavelengths, thus allowing a fast and specific control of defined molecular processes in biological systems.

Doctoral fellow Florian Lindner coupled the dynamic T3SS component with one part of this optogenetic interaction switch, while its other part was anchored to the bacterial membrane. By exposing bacteria and host cells to blue light, the availability of the T3SS components and consequently the function of the T3SS could be switched on and off.

Applying LITESEC to tumor research

Since the system is flexible in regard to which kind of proteins are injected, it can be used in many ways. In a collaboration with Thorsten Stiewe from the Philipps University in Marburg, the research group used the new system to attack and kill cultured tumour cells. The group now plans to use this technique for future basic research and for the development of further applications.

Learn more: Light drives injection

Go deeper with Bing News on:

Bacterial injection system

AACR Meeting News: Synlogic Presents Encouraging Data on Immunotherapy Drug
on April 12, 2021 at 5:00 am
Synlogic presented data at the American Association for Cancer Research (AACR) annual meeting from the SYNB1891 Phase I clinical trial.
How Biohackers Are Fighting A Two-front War On Antibiotic Resistance
on April 8, 2021 at 5:00 pm
Infections were miraculously cured with a simple injection or pill ... Cas systems into phages and using them to attack bacteria. The CRISPR system is programmed to search for and destroy ...
Polymixin Market 2021 : Emerging Opportunities, Industry Statistics, Market Size, Revenue and Volume Analysis by 2026 with Top Countries Data
on April 7, 2021 at 5:38 pm
Apr 07, 2021 (The Expresswire) -- According to 360 Research Reports, the “Polymixin Market" 2021 by Types (Oral, Injection ... bacterial cell membrane by interacting with its phospholipids. They are ...
The business and markets of liquid silicone rubber and liquid injection molding
on March 30, 2021 at 5:00 pm
In my presentation, I took a macro look at the business of liquid silicone from a raw material perspective, as well as a deeper focus of end-use markets for LSR and, most specifically, liquid ...
To Your Good Health: An injection in the arm can protect the whole body
on March 30, 2021 at 2:45 am
A vaccine usually consists of a weakened form of the bacteria or virus causing the disease to be protected against, or a small, noninfectious, purified part of the germ. After an injection ...

Go deeper with Google Headlines on:

Bacterial injection system

AACR Meeting News: Synlogic Presents Encouraging Data on Immunotherapy Drug - Genetic Engineering & Biotechnology News
April 12, 2021
How Do Pathogenic Bacteria Keep Up With Our Changing Gut Conditions? - Technology Networks
March 16, 2021
Heater-Cooler suit against LivaNova revived - Mass Device
April 12, 2021
Synlogic Unveils Promising Safety Data on its Immunotherapy Drug at AACR - Clinical OMICs News
April 12, 2021
Bacterial injection system with a light-controlled molecular switch - Phys.org
May 13, 2020

Go deeper with Bing News on:

Optogenetic injection system

An engineered channelrhodopsin optimized for axon terminal activation and circuit mapping
on April 12, 2021 at 4:12 am
Optogenetic tools such as channelrhodopsin-2 (ChR2 ... Cells were incubated with anti-Tau (Synaptic System, Goettingen, Germany), anti-MAP2 (Sigma-Aldrich, St. Louis, MO, USA), or anti-Bassoon (ENZO ...
GenSight Biologics Announces the Filing of its 2020 Universal Registration Document
on April 8, 2021 at 10:05 am
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal ...
Input-specific regulation of glutamatergic synaptic transmission in the medial prefrontal cortex by mGlu
on April 6, 2021 at 11:49 am
Metabotropic glutamate receptors (mGluRs) are G protein–coupled receptors that regulate various aspects of central nervous system processing in normal ... ex vivo brain slice electrophysiology, and ...
Optogenetic stimulation of cochlear neurons activates the auditory pathway and restores auditory-driven behavior in deaf adult gerbils
on April 4, 2021 at 5:01 pm
5 Auditory Neuroscience and Optogenetics Group, German Primate Center ... testing oCI in other species with a hearing system more closely resembling human condition is critical to understand the ...
First Four Patients In Bionic Sight’s Optogenetic Gene Therapy Trial Are Able To Detect Light And Motion
on March 30, 2021 at 4:03 am
These results provide substantial evidence that BS01 is reaching the targeted cells and expressing the optogenetic protein ... their baseline sensitivity (pre-injection), and the two that received ...